Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OMNICELL, INC. Director's Dealing 2017

Feb 10, 2017

31980_dirs_2017-02-10_83524946-d2cf-40f5-b3db-3d72e2ae3662.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OMNICELL, Inc (OMCL)
CIK: 0000926326
Period of Report: 2017-02-08

Reporting Person: LIPPS RANDALL A (Director, Chairman, President, and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-02-08 Common Stock A 16350 Acquired 192355 Direct
2017-02-08 Common Stock A 54500 Acquired 244705 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-02-08 Stock Option (Right to Buy) $36.70 A 134160 Acquired 2027-02-08 Common Stock (134160) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 143034 Direct
Common Stock 393228 Indirect
Common Stock 15549 Indirect

Footnotes

F1: Shares held in trust with Mr. Lipps' wife.

F2: Shares held in trust for the benefit of Mr. Lipps' children.

F3: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years.

F4: Shares shall vest ratably over 48 month period, with a year cliff.

F5: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance.